Bortezomib overcomes MGMT-related resistance of glioblastoma cell lines to temozolomide in a schedule-dependent manner. [electronic resource]
Producer: 20140414Description: 1169-81 p. digitalISSN:- 1573-0646
- Antineoplastic Agents -- administration & dosage
- Boronic Acids -- administration & dosage
- Bortezomib
- Cell Line, Tumor
- Dacarbazine -- administration & dosage
- Drug Resistance, Neoplasm -- drug effects
- Humans
- Hypoxia-Inducible Factor 1, alpha Subunit -- metabolism
- Mitogen-Activated Protein Kinases -- metabolism
- NF-kappa B -- metabolism
- O(6)-Methylguanine-DNA Methyltransferase -- antagonists & inhibitors
- Proto-Oncogene Proteins c-akt -- metabolism
- Pyrazines -- administration & dosage
- STAT3 Transcription Factor -- metabolism
- Temozolomide
- Tumor Suppressor Protein p53 -- metabolism
No physical items for this record
Publication Type: Journal Article
There are no comments on this title.
Log in to your account to post a comment.